{"id":17028,"date":"2026-10-08T14:23:32","date_gmt":"2026-10-08T14:23:32","guid":{"rendered":"https:\/\/www.sanner-group.com\/?post_type=blog&p=17028"},"modified":"2026-10-21T13:54:05","modified_gmt":"2026-10-21T13:54:05","slug":"drug-delivery-devices-past-and-future","status":"publish","type":"blog","link":"https:\/\/www.sanner-group.com\/insights\/blog\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\/","title":{"rendered":"Drug Delivery Devices Past and Future: A Retrospective on Innovation, Achievement, and Hard Lessons"},"content":{"rendered":"\n


The drug delivery device landscape is rich with brilliant ideas that never quite made it to patients or were launched but achieved limited commercial success. Some failed quietly in development. Others launched with fanfare only to be withdrawn. A few still linger in limbo – technically alive but commercially dormant. Together, they form a fascinating catalogue of ambition, engineering ingenuity, patient focus, regulatory friction, and market reality.<\/p>\n\n\n\n


Below is a tour through the major categories of devices that have struggled to achieve their potential. We cover why they struggled, and what their stories reveal about the future of drug delivery.<\/p>\n\n\n\n


This article was written in the spirit of learning from common challenges and educating the next generation of drug delivery pioneers. The teams behind these innovations often brought a wealth of talent and expertise. Most of the device categories discussed below have protagonists that currently are working hard to bring their devices to market or increase their market share if on the market. This article does not take a view on their merits or future chances of success. Rather, it is an opportunity to learn from experiences where others have struggled so that, together with our peers in the drug delivery devices ecosystem, we can maximize the success of innovation so that patients have devices that are increasingly effective, usable, safe, and economical.<\/p>\n\n\n\n


1. Needle-free Injectors: A Perennial Promise That Rarely Sticks<\/strong><\/p>\n\n\n\n


Needle-free injection has been a recurring dream for decades: painless, fast, sharps-free, and potentially self-administered. Yet relatively few devices have made it to market. Needle-free technology has achieved most of its success in the vaccine market where HCPs provide the administration.<\/p>\n\n\n\n


Challenges<\/strong><\/p>\n\n\n\n


\u00b7 Inconsistent dose delivery – especially with viscous biologics. Dose volume can be controlled, but jet geometry and penetration depth are strongly dependent on the formulation viscosity. Most drug manufacturing systems control the concentration of active pharmaceutical ingredients or biologic. Viscosity can vary significantly because the curve of viscosity versus concentration tends to be steep and non-linear at high concentrations.
\u00b7 Skin variability \u2014 age, hydration, and anatomy all affect jet penetration.
\u00b7 Pain perception \u2014 needle-free does not mean pain free, and the pain studies have not convinced the market to switch to needle-free drug delivery.
\u00b7 Complexity and cost \u2014 devices were often bulky, expensive, required special training, and\/or manufacturing processes could be more complex.
\u00b7 Non-standard containers \u2013 most implementations require drug containers that are different from standard pharmaceutical cartridges and syringes. These bring risks in drug stability, filling, and device verification such as dose accuracy and free-fall tests.
\u00b7 Regulatory caution\u2014cross contamination concerns after early multiuse jet injectors.
Notable examples
\u00b7 Comfort-In is a spring-based jet injector kit available in 4 countries plus the European Union.
\u00b7 Injex30 is approved for use in the US, EU, and China with a special focus on injecting anesthetics for dentistry.
\u00b7 PharmaJet Stratis\/Tropis: used in vaccination settings but has not yet achieved significant injector market share compared to needle-based devices.
\u00b7 Biojector: widely used in the 1990s and 2000s, eventually discontinued.
\u00b7 Zogenix DosePro: approved for sumatriptan; commercial uptake limited; discontinued product due to commercial reasons.
\u00b7 Merck Group explored a needle-free injector for Rebif called RebiJet in the mid-2000s which was based on the Intraject technology. It never reached commercial launch, probably due to the shift of focus to the RebiSmart reusable electromechanical injector and the Rebidose single-use autoinjector. The technology went on to become Crossject\u2019s Zeneo which is still in development.
\u00b7 Portal Instruments developed Prime, an electromechanical needle-free injector which is not commercialized yet. The company has now adopted the core technology for a needle-based reusable electromechanical autoinjector using pre-filled syringes.<\/p>\n\n\n\n


Needle-free injectors are technologically impressive but have struggled to achieve the commercial success of needle-based injectors.<\/p>\n\n\n\n


2. Transdermal Patches: The Rise, Plateau, and Quiet Retreat<\/strong><\/p>\n\n\n\n


Transdermal delivery had its golden era with patches developed to deliver medicines such as:<\/p>\n\n\n\n


\u2022 Nicotine replacement therapy,
\u2022 Pain management e.g. fentanyl or morphine,
\u2022 Contraceptives,
\u2022 Hormone replacement therapy e.g., estrogen or testosterone,
\u2022 Cardiovascular treatment e.g., nitroglycerin, or
\u2022 Motion sickness reduction e.g. scopolamine.<\/p>\n\n\n\n


However, the next generation of \u201cactive\u201d or \u201cenhanced\u201d patches often failed to reach the market.<\/p>\n\n\n\n


Challenges<\/strong><\/p>\n\n\n\n


Skin is a formidable barrier, especially for large molecules.<\/p>\n\n\n\n


\u00b7 Microneedle patches faced challenges with drug load, repeatable pharmacokinetics, manufacturing, stability, usability, skin reactions and regulatory hurdles.
\u00b7 Thermal ablation patches never scaled beyond early trials.
Notable examples
\u00b7 Exelon Patch was approved in 2025 for the treatment of mild to moderate Alzheimer’s disease. Developed by Noven Pharmaceuticals, the patch delivers the drug, rivastigmine, through the skin, offering a more convenient alternative to existing oral medications
\u00b7 Gylden Pharma\u2019s Titanium Microneedle Platform is a titanium microneedle patch developed by ALZA, spun out as Macroflux which became Zosano. Zosano had a partnering deal with Novo Nordisk (2014-2015) on insulin delivery but ultimately filed for bankruptcy in 2022 when the FDA requested more bioequivalence data. Gylden Pharma is pending regulatory approval for using the technology to deliver zolmitriptan.
\u00b7 PassPort uses an applicator to create microscopic porous channels in the skin before a patch is applied. The company’s lead preclinical candidate is a CNS therapeutic in development in the US via the 505(b) (2) pathway and they released interim results from a Phase 1 trial in 2024.
\u00b7 Various iontophoretic patches have been launched. These drive drug through the skin using electric fields. One example, Ionsys for delivering fentanyl, was launched in the European Union and United States for postoperative pain in 2006 but was recalled from the EU in 2008 due to a corrosion issue that could cause unintended fentanyl release and was withdrawn in 2009. It was relaunched in some markets in 2015 then voluntarily withdrawn from the US market in 2017 for commercial reasons. Most current iontophoretic patches are used for physiotherapy. They tend to be medical devices rather than combination products, and the drugs they are used for include hydrocortisone, acetic acid, dexamethasone, and lidocaine. Examples are IontoPatch and InotoGo.
\u00b7 Sonophoretic patches such as SonoPrep from Echo Therapeutics use ultrasound to disrupt the stratum corneum and enable drug to penetrate the skin. SonoPrep was approved in 2004, but Echo pivoted towards its sonophoresis-enabled glucose monitoring platform and the company shut down in 2016.<\/p>\n\n\n\n


The transdermal patch field continues to attract interest such as several active investigations for intradermal vaccine delivery.<\/p>\n\n\n\n


3. Gas Powered Injectors: Elegant Engineering, Limited Adoption<\/strong><\/p>\n\n\n\n


Gas powered autoinjectors use compressed gas (often CO\u2082, nitrogen or argon) to drive a plunger. They offer smoother injection profiles than springs and the ability to inject viscous biologics in a reasonable injection time.<\/p>\n\n\n\n


Challenges<\/strong><\/p>\n\n\n\n


\u00b7 Cost and complexity\u2014gas cannister add manufacturing and regulatory burden.
\u00b7 Temperature sensitivity\u2014gas pressure varies with ambient conditions.
\u00b7 Bulky form factors\u2014gas-powered injectors can be larger compared to spring-based devices once piercers, valves, and seals are included. However, gas power is typically used in applications that require more force or energy than can be provided by a spring so comparisons must be fair.
\u00b7 Needs clear clinical advantage to justify premium pricing.<\/p>\n\n\n\n


Examples that made it to market<\/p>\n\n\n\n


\u00b7 Auvi-Q was developed to deliver epinephrine for anaphylactic shock. It was launched in 2012 but recalled in 2015 due to the risk of inaccurate dose delivery. It was relaunched in 2017, and the same platform is used to deliver naloxone in the Rapid Opioid Countermeasure System.
\u00b7 The iJect \/ BioJect family mentioned above.<\/p>\n\n\n\n


Examples that were cancelled<\/p>\n\n\n\n


\u00b7 Ovaleap\u2019s gas powered injector prototypes were never commercialized.
\u00b7 Bespak Syrina and Viscala were never commercialized.<\/p>\n\n\n\n


Examples that are in development<\/p>\n\n\n\n


\u00b7 Windgap DualFlo, OneMix, and MultiMix.
\u00b7 CrossJect Zeneo
\u00b7 AltaViz AltaVISC
\u00b7 Congruence Autoinjector
\u00b7 SMC\u2019s Bios platform<\/p>\n\n\n\n


Spring-based autoinjectors are difficult to beat on simplicity and cost for drug formulations with modest dose volume and viscosity. Other actuator technologies such as motors tend to compete with gas power where large dose volumes or high viscosities need to be delivered.<\/p>\n\n\n\n


4. Connected Devices: A Wave of Smart Tech That Has Not Yet Found Its Market<\/strong><\/p>\n\n\n\n


The mid-2010s saw a surge of enthusiasm for \u201csmart injectors,\u201d Bluetooth-enabled autoinjectors, smart inhalers, adherence trackers, and cloud connected drug delivery ecosystems.<\/p>\n\n\n\n


Challenges<\/strong><\/p>\n\n\n\n


\u00b7 Low patient demand\u2014most patients don\u2019t want or need connectivity.
\u00b7 Reimbursement gaps\u2014payers rarely fund digital addons.
\u00b7 Cybersecurity and privacy concerns.
\u00b7 Device complexity\u2014more components, more failure modes.
\u00b7 Timing with respect to drug lifecycles\u2014hard to justify connected device development at the time of drug development, or multiyear digital investments.
Pharma had a difficult time looking beyond the drug product, struggled where to place the responsibility in the organization, and how to define Return-On-Investment.<\/p>\n\n\n\n


Notable examples<\/strong><\/p>\n\n\n\n


\u00b7 Merck Group\u2019s easypod was launched in 2007 and its second generation introduced connectivity with easypod Connect in 2011. It continues to be on the market, now in its third generation.
\u00b7 Connected insulin pens have found market success with an estimated value of USD 905 million and an estimated Compound Annual Growth Rate of 11.96%. Biocorp\u2019s Mallaya and Innovation Zed\u2019s InsulCheck DOSE\u2122 are connected caps for a variety of disposable insulin pens. The Common Sensing GoCap insulin pen add-on became part of the Bigfoot Unity diabetes management system, now owned by Abbott. Several other connected pen caps have come and gone, such as Timesulin.
\u00b7 Propeller Health and Adherium developed smart add-ons for inhalers but had limited uptake. Propeller was acquired by Resmed in 2018 then shut down. Adherium\u2019s Hailie platform is commercialized in the USA with shipments of around 1400 devices per quarter.
\u00b7 Teva launched the connected inhaler Digihaler for ProAir, ArmonAir, and AirDuo starting in 2019 but withdrew the devices from the market in April 2024.
\u00b7 Bayer markets the BETACONNECT connected electronic autoinjector for Betaseron to treat multiple sclerosis.
\u00b7 There are other connected autoinjector pre-market programs such as SHL\u2019s Elexy and autoinjector add-ons such as Ypsomed\u2019s SmartPilot, which has 510(k) clearance.
\u00b7 Lilly is going to discontinue the Tempo\u2122 Personalized Diabetes Management Platform at the end of 2026.
The lesson: connectivity must solve a real problem, not just add a feature. The value proposition (business case) needs to be convincing, and the benefits to patients and clinicians must be compelling if they are being asked to perform any actions related to connectivity.<\/p>\n\n\n

\n
\n
\n
\n
\n \"\"<\/picture> <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/section>\n\n\n\n


5. Solid Dose and Powder Injection Systems: High Hopes, Hard Realities<\/strong><\/p>\n\n\n\n


Solid dose injectors and powder jet systems promised needle-free delivery of vaccines and biologics using microprojectiles or high velocity powder streams.<\/p>\n\n\n\n


Challenges<\/strong><\/p>\n\n\n\n


\u00b7 Dose variability\u2014especially with powder dispersal. For example, one study on excised human skin membranes showed that only 50% of the powder formulation left the device and the ejected powder had significant comminution [fragmentation].
\u00b7 Complex device mechanics.
\u00b7 Regulatory uncertainty\u2014novel routes raise safety questions.
\u00b7 Cold chain and stability issues\u2014ironically, many systems did not eliminate cold chain needs.<\/p>\n\n\n\n


Notable examples on the market<\/strong><\/p>\n\n\n\n


\u00b7 Solid dose implants for ophthalmic use such as Iluvien, Ozurdex, and Durysta. These are solid doses but are delivered via a needle so they are distinct from the needle-free solid dose injector such as aVaxMed and PowderJect.<\/p>\n\n\n\n


Notable examples in development<\/strong><\/p>\n\n\n\n


\u00b7 aVaxMed: Spring-driven solid dose injector. Formerly Glide Pharma then Enesi Pharma.<\/p>\n\n\n\n


Notable examples that have ceased development<\/strong><\/p>\n\n\n\n


\u2022 PowderJect: the technology injected a stream of dry powder particles. It was discontinued before reaching the market, probably due the changing competitive environment: in the late 1990s disposable syringes improved, needlestick protection systems became more widely adopted, autoinjectors became common, and needle-based vaccine administration remained inexpensive.
Lessons from the experiences of solid dose injectors include:
\u2022 Solid doses are a compelling option when extended release is required, for example in ophthalmic implants.
\u2022 For other applications such as vaccines, the value proposition must be convincing versus needle-based liquid injections, especially in the modern era where cold chain distribution and needlestick protection have improved greatly.<\/p>\n\n\n\n


6. Inhaled Biologics: The Exubera Effect and Its Aftermath<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

Inhaled insulin was once heralded as the future of diabetes care. If inhaled insulin had been very successful, then it would have paved the way for many more inhaled systemic biologics. Instead, it became a cautionary tale.<\/p>\n\n\n\n


Challenges<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

\u00b7 Large devices (notably for Exubera, less so in other cases such as Afrezza).
\u00b7 Pulmonary safety concerns\u2014long term effects of inhaled proteins remain uncertain.
\u00b7 Variable absorption\u2014affected by lung function, technique, and comorbidities.
\u00b7 Cost and reimbursement challenges.
\u00b7 Competition from improved injectable pens and pumps.<\/p>\n\n\n\n


Notable examples<\/strong><\/p>\n\n\n\n


\u00b7 Exubera (Pfizer): launched 2006, withdrawn 2007.
\u00b7 Afrezza (MannKind): available on the market but not yet a blockbuster at USD 75m sales per year.
\u00b7 Lilly-Alkermes AIR insulin system which reached Phase 2 clinical trials.
\u00b7 Novo Nordisk-Aradigm AERx iDMS (liquid-based insulin system) reached Phase 3 clinical trials. The liquid strips and complex electronic device would have led to high cost-of-goods.
\u00b7 Inhaled GLP1 and other biologics\u2014multiple programs discontinued.<\/p>\n\n\n\n


The lungs are a promising but unforgiving route. Dry powder inhalers have limits around dose mass and drug suitability for micronization. Pressurized metered dose inhalers present formulation challenges with approved propellants. Nebulizers do not have these drawbacks and can be used in Phase 1 and 2 clinical trials onwards, but a successful platform needs to support easy adaptability to the given drug formulation and viscosity.<\/p>\n\n\n

\n
\n
\n
\n
\n \"\"<\/picture> <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/section>\n\n\n\n

<\/p>\n\n\n\n

7. On-body Injectors: A Category With Successes And High Potential but Several Casualties<\/strong><\/p>\n\n\n\n


On-body injectors (OBIs, also called \u201cpatch pumps\u201d, \u201cOn Body Delivery Systems\u201d, or \u201cbolus injectors\u201d) are designed for self-administration of large volume biologics, ideally negating the need for patient visits to infusion centers.<\/p>\n\n\n\n


This category of devices has seen some notable successes and shows that new device categories are possible if the clinical need is present, the technology is not too risky, and the regulatory path is like other successful device formats.<\/p>\n\n\n\n


Challenges<\/strong><\/p>\n\n\n\n


\u00b7 Skin adhesion or reaction issues.
\u00b7 User anxiety\u2014patients uncomfortable wearing a device for more than a few minutes.
\u00b7 Complexity and cost\u2014more components than prefilled syringes or autoinjectors.
\u00b7 Manufacturing challenges\u2014sterility, assembly, and reliability.
\u00b7 Drug device integration issues\u2014especially with viscous or sensitive biologics.
\u00b7 Technology unfamiliarity and patient adoption perception with stakeholders.<\/p>\n\n\n\n


Notable examples of devices which have reached the market<\/strong><\/p>\n\n\n\n


\u00b7 West Pharmaceutical Services SmartDose:
o Launched then discontinued in the 3.5 mL variant for Amgen\u2019s Repatha. Patients were advised to switch from using one on-body injector to three autoinjectors.
o Launched for AbbVie\u2019s Skyrizi in 2020. AbbVie acquired manufacturing and supply rights to SmartDose 3.5 mL in January 2026
o Approved in 2022 but never launched for Alexion\u2019s Ultomiris (ravulizumab).
o The 10 mL variant was approved in the USA in October 2022 for scPharmaceuticals Furoscix to treat congestive heart failure. It delivers 80 mg of Furoscix over 5 hours.
\u00b7 Neulasta Onpro (Insulet). At the time of writing, more than 1 million patients have used Neulasta Onpro.
\u00b7 EMPAVELI Enfuse (Enable Injections) approved by FDA in 2023.
\u00b7 UDENYCA Sorrel (LTS Lohmann) was launched in 2024.
\u00b7 Lasix Onu SensAir (Gerresheimer) was approved by FDA in 2025.<\/p>\n\n\n\n


Notable examples of devices in development<\/strong><\/p>\n\n\n\n


\u00b7 Prefilled single use on-body injectors such as BD\u2019s Libertas and Ypsomed\u2019s YpsoDose.
\u00b7 Part-reusable motor-driven on-body injectors such as Stevanato Group\u2019s Vertiva and Nemera\u2019s Symbioze.
\u00b7 Subcuject\u2019s osmosis-driven on-body injector.<\/p>\n\n\n\n


Several on-body injectors have been discontinued such Ratio Inc.\u2019s hydrogel-powered injector or Bespak\u2019s gas-powered Lapas.<\/p>\n\n\n\n

8. Nasal Delivery Of Biologics: Can Be Fast and Simple, But Variable<\/strong><\/p>\n\n\n\n


Nasal delivery has been successful for small molecules (e.g., naloxone, sumatriptan, epinephrine) but attempts to expand into biologics and vaccines have been rocky.<\/p>\n\n\n\n


Challenges<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n


\u00b7 Mucociliary clearance\u2014drug is swept away quickly.
\u00b7 Limited absorption of large molecules.
\u00b7 Irritation and tolerability issues.
\u00b7 Device variability\u2014spray plume geometry, delivered dose, and droplet size distribution depend on pump pressure (therefore typically the force provided by the user), nozzle tolerances, and formulation properties (viscosity and surface tension for liquids, particle morphology and electrotribology for dry powders).
\u00b7 Notable examples<\/p>\n\n\n\n

\u00b7 Nasal insulin programs\u2014multiple discontinued.
\u00b7 Nasal vaccines\u2014 many candidates failed to show adequate immunogenicity, but FluMist (influenza virus subtypes A and B) got FDA approval first in 2012 and in 2024 for self or caregiver administration
\u00b7 Baqsimi (glucagon) delivered by Aptar\u2019s Unidose powder device.
\u00b7 NOSA and Hogne TrigeNas nose plugs in development.<\/p>\n\n\n\n


Nasal delivery remains attractive but technically unforgiving.<\/p>\n\n\n\n


9. Why So Many Device Categories Struggle<\/strong><\/p>\n\n\n\n


Across categories, the same patterns recur:<\/p>\n\n\n\n


\u00b7 Biology beats engineering
The human body is not a passive receptacle. Skin, lungs, nasal mucosa, and subcutaneous tissue all impose constraints that clever engineering cannot always overcome.<\/p>\n\n\n\n

\u00b7 Simplicity wins<\/p>\n\n\n\n

\u00b7 Patients, clinicians, and payers gravitate toward devices that are:<\/p>\n\n\n\n

\u00b7 Small
\u00b7 Intuitive, minimal use steps
\u00b7 Reliable
\u00b7 Low technology complexity, risk and cost
\u00b7 Anything more complex must deliver a clear clinical benefit.
\u00b7 Integration is hard<\/p>\n\n\n\n


Drug device combination products require:<\/p>\n\n\n\n


\u00b7 Timing for market pull and technology push must be right: the pharmaceutical company needs the product just at the right time
\u00b7 Stability compatibility
\u00b7 Regulatory coordination, preferred technology has been already approved by a regulatory agency
\u00b7 Manufacturing harmonization e.g. using a standard primary container enables reuse of filling technology, and provides potential as platform technology
\u00b7 Speed to market to stay ahead<\/p>\n\n\n\n


Many programs fail at these interfaces.<\/p>\n\n\n\n


The market is ruthless<\/p>\n\n\n\n


Even technically successful devices can die if:<\/p>\n\n\n\n


\u00b7 Reimbursement is weak
\u00b7 Training burden is high
\u00b7 Competitors launch simpler alternatives
\u00b7 The target population might be small<\/p>\n\n\n\n


Adoption takes time
Successful launches of products by startup companies tend to take more than 10 years. For example, Kaleo (formerly Intelliject) was founded in 2000 and launched Auvi-Q in 2012, Sensile Medical (now part of Gerresheimer) was founded in 2004 and launched the D-MINE pump in 2019, and Enable Injections was founded in 2010 and launched enFuse in 2023.<\/p>\n\n\n\n

<\/p>\n\n\n\n

10. What We Can Learn About the Future<\/strong><\/p>\n\n\n\n


Despite the challenges, innovation and evolution in drug delivery devices continue at pace. The next generation of devices will likely succeed if they:<\/p>\n\n\n\n


\u00b7 Solve a real clinical or workflow problem
\u00b7 Reduce burden, not add features
\u00b7 Integrate seamlessly into existing care pathways
\u00b7 Demonstrate clear economic value
\u00b7 Apply to diverse patient populations
\u00b7 Get the right fit and timing for market pull and technology push
\u00b7 Provide advantage versus competitor devices
\u00b7 Address why similar technologies struggled<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

Reference lists available on request. <\/p>\n\n\n\n

<\/p>\n\n\n\n

Written by: Toam Oakley, VP Strategic Partnership, Sanner and Ulrich Bruggeman, Takeda. <\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

Tom Oakley, Vice-President Strategic Partnerships at Sanner Group (previously Springboard), leads engineering and scientific teams developing new injection devices, pumps and inhalers. <\/p>\n\n\n\n

<\/p>\n\n\n\n

Ulrich Bruggemann, Lead, Advanced Drug Delivery Technical Development, at Takeda Pharmaceuticals, has been working on the development of medical device and diagnostics technologies and products for over 30 years in the US and Germany. Mr Bruggemann is an employee of Takeda Development Center Americas, Inc, a subsidiary of Takeda Pharmaceutical Inc and owns stock.<\/p>\n\n\n\n

<\/p>\n","protected":false},"featured_media":15830,"template":"","blog_category":[],"class_list":["post-17028","blog","type-blog","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\nDrug Delivery Devices Past and Future: A Retrospective on Innovation, Achievement, and Hard Lessons - Sanner Group<\/title>\n<meta name=\"description\" content=\"Find out about past drug delivery devices and insights as to what the future looks like from experts at Sanner\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sanner-group.com\/hu\/insights\/blog\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\/\" \/>\n<meta property=\"og:locale\" content=\"hu_HU\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug Delivery Devices Past and Future: A Retrospective on Innovation, Achievement, and Hard Lessons - Sanner Group\" \/>\n<meta property=\"og:description\" content=\"Find out about past drug delivery devices and insights as to what the future looks like from experts at Sanner\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sanner-group.com\/insights\/blog\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\/\" \/>\n<meta property=\"og:site_name\" content=\"Sanner Group\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-21T13:54:05+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Becs\u00fclt olvas\u00e1si id\u0151\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 perc\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sanner-group.com\\\/insights\\\/blog\\\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\\\/\",\"url\":\"https:\\\/\\\/www.sanner-group.com\\\/insights\\\/blog\\\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\\\/\",\"name\":\"Drug Delivery Devices Past and Future: A Retrospective on Innovation, Achievement, and Hard Lessons - Sanner Group\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sanner-group.com\\\/hu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sanner-group.com\\\/insights\\\/blog\\\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sanner-group.com\\\/insights\\\/blog\\\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sanner-group.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/drug-pump-sanner-body-e1790592799208.avif\",\"datePublished\":\"2026-10-08T14:23:32+00:00\",\"dateModified\":\"2026-10-21T13:54:05+00:00\",\"description\":\"Find out about past drug delivery devices and insights as to what the future looks like from experts at Sanner\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sanner-group.com\\\/insights\\\/blog\\\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\\\/#breadcrumb\"},\"inLanguage\":\"hu\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sanner-group.com\\\/insights\\\/blog\\\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"hu\",\"@id\":\"https:\\\/\\\/www.sanner-group.com\\\/insights\\\/blog\\\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sanner-group.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/drug-pump-sanner-body-e1790592799208.avif\",\"contentUrl\":\"https:\\\/\\\/www.sanner-group.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/drug-pump-sanner-body-e1790592799208.avif\",\"width\":1490,\"height\":642},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sanner-group.com\\\/insights\\\/blog\\\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sanner-group.com\\\/hu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Drug Delivery Devices Past and Future: A Retrospective on Innovation, Achievement, and Hard Lessons\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sanner-group.com\\\/hu\\\/#website\",\"url\":\"https:\\\/\\\/www.sanner-group.com\\\/hu\\\/\",\"name\":\"Sanner Group\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sanner-group.com\\\/hu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"hu\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Drug Delivery Devices Past and Future: A Retrospective on Innovation, Achievement, and Hard Lessons - Sanner Group","description":"Find out about past drug delivery devices and insights as to what the future looks like from experts at Sanner","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sanner-group.com\/hu\/insights\/blog\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\/","og_locale":"hu_HU","og_type":"article","og_title":"Drug Delivery Devices Past and Future: A Retrospective on Innovation, Achievement, and Hard Lessons - Sanner Group","og_description":"Find out about past drug delivery devices and insights as to what the future looks like from experts at Sanner","og_url":"https:\/\/www.sanner-group.com\/insights\/blog\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\/","og_site_name":"Sanner Group","article_modified_time":"2026-10-21T13:54:05+00:00","twitter_card":"summary_large_image","twitter_misc":{"Becs\u00fclt olvas\u00e1si id\u0151":"14 perc"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sanner-group.com\/insights\/blog\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\/","url":"https:\/\/www.sanner-group.com\/insights\/blog\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\/","name":"Drug Delivery Devices Past and Future: A Retrospective on Innovation, Achievement, and Hard Lessons - Sanner Group","isPartOf":{"@id":"https:\/\/www.sanner-group.com\/hu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sanner-group.com\/insights\/blog\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\/#primaryimage"},"image":{"@id":"https:\/\/www.sanner-group.com\/insights\/blog\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sanner-group.com\/wp-content\/uploads\/2026\/09\/drug-pump-sanner-body-e1790592799208.avif","datePublished":"2026-10-08T14:23:32+00:00","dateModified":"2026-10-21T13:54:05+00:00","description":"Find out about past drug delivery devices and insights as to what the future looks like from experts at Sanner","breadcrumb":{"@id":"https:\/\/www.sanner-group.com\/insights\/blog\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\/#breadcrumb"},"inLanguage":"hu","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sanner-group.com\/insights\/blog\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\/"]}]},{"@type":"ImageObject","inLanguage":"hu","@id":"https:\/\/www.sanner-group.com\/insights\/blog\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\/#primaryimage","url":"https:\/\/www.sanner-group.com\/wp-content\/uploads\/2026\/09\/drug-pump-sanner-body-e1790592799208.avif","contentUrl":"https:\/\/www.sanner-group.com\/wp-content\/uploads\/2026\/09\/drug-pump-sanner-body-e1790592799208.avif","width":1490,"height":642},{"@type":"BreadcrumbList","@id":"https:\/\/www.sanner-group.com\/insights\/blog\/drug-delivery-devices-past-and-future-a-retrospective-on-innovation-achievement-and-hard-lessons\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sanner-group.com\/hu\/"},{"@type":"ListItem","position":2,"name":"Drug Delivery Devices Past and Future: A Retrospective on Innovation, Achievement, and Hard Lessons"}]},{"@type":"WebSite","@id":"https:\/\/www.sanner-group.com\/hu\/#website","url":"https:\/\/www.sanner-group.com\/hu\/","name":"Sanner Group","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sanner-group.com\/hu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"hu"}]}},"permalink_manager":null,"_links":{"self":[{"href":"https:\/\/www.sanner-group.com\/hu\/wp-json\/wp\/v2\/blog\/17028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sanner-group.com\/hu\/wp-json\/wp\/v2\/blog"}],"about":[{"href":"https:\/\/www.sanner-group.com\/hu\/wp-json\/wp\/v2\/types\/blog"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sanner-group.com\/hu\/wp-json\/wp\/v2\/media\/15830"}],"wp:attachment":[{"href":"https:\/\/www.sanner-group.com\/hu\/wp-json\/wp\/v2\/media?parent=17028"}],"wp:term":[{"taxonomy":"blog_category","embeddable":true,"href":"https:\/\/www.sanner-group.com\/hu\/wp-json\/wp\/v2\/blog_category?post=17028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}